Howard Melissa D, Hood Elizabeth D, Greineder Colin F, Alferiev Ivan S, Chorny Michael, Muzykantov Vladimir
Department of Pharmacology and Center for Targeted Therapeutics and Translational Nanomedicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania 19104, United States.
Mol Pharm. 2014 Jul 7;11(7):2262-70. doi: 10.1021/mp400677y. Epub 2014 Jun 17.
Oxidative stress and inflammation are intertwined contributors to numerous acute vascular pathologies. A novel dual bioactive nanoparticle with antioxidant/anti-inflammatory properties was developed based on the interactions of tocopherol phosphate and the manganese porphyrin SOD mimetic, MnTMPyP. The size and drug incorporation efficiency were shown to be dependent on the amount of MnTMPyP added as well as the choice of surfactant. MnTMPyP was shown to retain its SOD-like activity while in intact particles and to release in a slow and controlled manner. Conjugation of anti-PECAM antibody to the nanoparticles provided endothelial targeting and potentiated nanoparticle-mediated suppression of inflammatory activation of these cells manifested by expression of VCAM, E-selectin, and IL-8. This nanoparticle technology may find applicability with drug combinations relevant for other pathologies.
氧化应激和炎症是导致众多急性血管病变的相互关联的因素。基于生育酚磷酸酯与锰卟啉超氧化物歧化酶模拟物MnTMPyP的相互作用,开发了一种具有抗氧化/抗炎特性的新型双生物活性纳米颗粒。结果表明,纳米颗粒的大小和药物包封效率取决于所添加的MnTMPyP的量以及表面活性剂的选择。研究表明,MnTMPyP在完整颗粒中保持其超氧化物歧化酶样活性,并以缓慢且可控的方式释放。将抗PECAM抗体与纳米颗粒偶联可实现内皮靶向,并增强纳米颗粒介导的对这些细胞炎症激活的抑制作用,这种抑制作用通过血管细胞黏附分子(VCAM)、E-选择素和白细胞介素-8(IL-8)的表达得以体现。这种纳米颗粒技术可能适用于与其他病症相关的药物组合。